{"entity":{"id":"nct04910022","kind":"trial","name":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is active not recruiting.","summary":"The registry lists NCT04910022 as active not recruiting, last updated 2025-08-19. Enrolment is 150 planned participants, an estimate. Interventions: NMS-03305293, Temozolomide. Primary measures include Phase 1: Number of Participants with first-cycle dose limiting toxicity; Phase 2: Objective Response Rate. No results are posted in the registry; this does not exclude separate publications.","status":"active","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT04910022","url":"https://clinicaltrials.gov/study/NCT04910022"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":["parp"],"drugs":["temozolomide","nms-03305293"],"companies":["nerviano-medical-sciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04910022","phase":"1/2","setting":"A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients With Recurrent Glioblastoma","sponsor":"Nerviano Medical Sciences","participation":[{"nct":"NCT04910022","source":"https://clinicaltrials.gov/study/NCT04910022","fetchedAt":"2026-10-07T16:53:30.019Z","studySha256":"4d79beca5f00a37dd1ede9574e483a938a202c32ca5f39b2c8ba3379b25485ba","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-08-19","leadSponsor":"Nerviano Medical Sciences","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":150,"enrolmentType":"ESTIMATED","siteCount":18,"recruitingSiteCount":0,"countries":["Italy","Netherlands","Puerto Rico","Switzerland","United States"]}],"started":"2021-12-01","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04910022/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"nms-03305293","kind":"drug","name":"NMS-03305293","route":"/drugs/nms-03305293/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"nerviano-medical-sciences","kind":"company","name":"Nerviano Medical Sciences","route":"/companies/nerviano-medical-sciences/"}]}}